Regeneron — Third Quarter 2026 Earnings Summary

Regeneron Pharmaceuticals reported third-quarter 2026 total revenues of $5.1 billion, representing a 36% increase from the prior year, driven by record sales of Dupixent, EYLEA HD, and Libtayo. The company's GAAP net income per diluted share rose 35% to $18.45, while non-GAAP net income per diluted share increased 70% to $20.07. Key operational milestones included the FDA approval of Pasatru for fibrodysplasia ossificans progressiva and an expanded collaboration with Sanofi that generated a $1.0 billion up-front payment. Additionally, the company announced positive clinical data for several pipeline candidates, including cemdisiran for generalized myasthenia gravis and RNAi therapies for metabolic dysfunction-associated steatotic liver disease.